Abstract
Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma
Highlights
400,000 new cases of renal cell carcinoma (RCC) are diagnosed worldwide each year, with a resultant 175,000 deaths[1]
Patients diagnosed with synchronous metastatic renal cell carcinoma who were fit for surgery were offered upfront cytoreductive nephrectomy as standard-of-care treatment
The role of cytoreductive nephrectomy in the treatment algorithm of patients presenting with synchronous metastatic RCC has evolved considerably since the original randomized trials were published in 2001
Summary
400,000 new cases of renal cell carcinoma (RCC) are diagnosed worldwide each year, with a resultant 175,000 deaths[1]. Both of these trials were published in 2001 and demonstrated survival-benefit for patients undergoing upfront cytoreductive nephrectomy in the setting of synchronous metastatic disease. The combined analysis showed an overall median survival of 13.6 months for patients undergoing nephrectomy followed by interferon alfa vs 7.8 months for interferon alone.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
